Drug Trial Radar · NCT04674761
Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome
Last checked: Nov 20, 2026Latest source record: Nov 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Mar 19, 2021
Primary completion
Sep 9, 2022
Study completion Sep 9, 2022
Sponsor
- Lead sponsor
- AlbireoIndustry
- Sponsor type
- Industry
- First posted
- Dec 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in Patients with Alagille Syndrome.
Conditions
- Alagille Syndrome
Interventions
OdevixibatDrug
Odevixibat is a small molecule and selective inhibitor of IBAT.
PlaceboDrug
Placebo identical in appearance to experimental drug (odevixibat).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Scratching ScoreTime frame: Change from baseline for each four-week average pruritis score to Month 6 (Weeks 21 to 24), in which baseline was calculated based on the 14 days before the start of treatment.
Locations
32 sites in 13 countries. Site status is shown where the registry gives one.
University of California - San Francisco
San Francisco, California
Johns Hopkins Hospital
Baltimore, Maryland
Boston Children's Hospital
Boston, Massachusetts
Children's Mercy Hospital and Clinics
Kansas City, Missouri
Icahn School of Medicine at Mount Sinai
New York, New York
Columbia University Medical Center
New York, New York
The Childrens Hospital at Montefiore Albert Einstein School of Medicine
The Bronx, New York
Oregon Health Science University School of Medicine
Portland, Oregon
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
Cliniques Universitaires Saint-Luc Bruxelles
Brussels, Belgium
CHU Sainte-Justine
Montreal, Quebec, Canada
Hôpital Femme Mère Enfant de Lyon
Bron, France
Antenne pédiatrique du CIC - Hopital Jeanne De Flandre
Lille, France
APHM
Marseille, France
Hopital Necker Enfants Malades
Paris, France
Charité-Universitätsmedizin Berlin
Berlin, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Universitätsklinik für Kinder-und Jugendmedizin Tübingen
Tübingen, Germany
Sharie Zedek
Jerusalem, Israel
Schneider Children's Medical Center of Israel
Petah Tikva, Israel
ASST Papa Giovanni XXIII
Bergamo, Italy
AOU Meyer
Florence, Italy
Azienda Ospedale Università Padova
Padova, Italy
Bambino Gesù Children's Hospital
Rome, Italy
University of Malaya Medical Centre
Kuala Lumpur, Malaysia
Universitair Medisch Centrum Groningen (UMCG)
Groningen, Netherlands
University Medical Centre Utrecht, WKZ
Utrecht, Netherlands
Starship Child Health
Auckland, New Zealand
Instytut Pomnik-Centrum Zdrowia Dziecka
Warsaw, Poland
Hacettepe Üniversitesi İhsan Doğramacı Çocuk Hastanesi
Ankara, Turkey (Türkiye)
Istanbul University Medical Faculty Hospital
Fatih, Turkey (Türkiye)
King's College Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.